Stock Market News
Akers Biosciences seals US distribution agreement for heparin test
Health information technology company Akers Biosciences has entered a three-year hospital distribution agreement covering the United States.
The national distribution agreement will see Diagnostica Stago market and sell Akers' PIFA PLUSS PF4 product, a test for heparin sensitivity, across its broad existing customer base of hospital laboratories.
John Gormally, chief executive of Akers Bio, said: "Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market."
The PIFA PLUSS PF4 is designed to rapidly determine, in under one hour, whether a patient being treated with widely used blood thinner heparin may be developing a reaction known heparin-induced thrombocytopenia, which can risk the limbs and life of patients.
According to Akers, there are approximately 4m tests for HIT conducted annually in the US using slower traditional methods which the company hopes to replace with its rapid alternative.
Phillippe Barroux, North America chief executive of Stago, said: "Stago is pleased to have selected PIFA PLUSS PF4 rapid assay as its only rapid test for heparin Platelet Factor 4 antibodies in the US. Our sales team is looking forward to communicating the compelling medical and economic benefits of this uniquely efficient and accurate test for heparin-induced thrombocytopenia to Stago's customers in line with our commitment to providing market leading hemostasis solutions to improve patient care."
As of 0839 GMT, Akers Biosciences' shares were up 2.73% at 56.50p.
The national distribution agreement will see Diagnostica Stago market and sell Akers' PIFA PLUSS PF4 product, a test for heparin sensitivity, across its broad existing customer base of hospital laboratories.
John Gormally, chief executive of Akers Bio, said: "Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market."
The PIFA PLUSS PF4 is designed to rapidly determine, in under one hour, whether a patient being treated with widely used blood thinner heparin may be developing a reaction known heparin-induced thrombocytopenia, which can risk the limbs and life of patients.
According to Akers, there are approximately 4m tests for HIT conducted annually in the US using slower traditional methods which the company hopes to replace with its rapid alternative.
Phillippe Barroux, North America chief executive of Stago, said: "Stago is pleased to have selected PIFA PLUSS PF4 rapid assay as its only rapid test for heparin Platelet Factor 4 antibodies in the US. Our sales team is looking forward to communicating the compelling medical and economic benefits of this uniquely efficient and accurate test for heparin-induced thrombocytopenia to Stago's customers in line with our commitment to providing market leading hemostasis solutions to improve patient care."
As of 0839 GMT, Akers Biosciences' shares were up 2.73% at 56.50p.
Related share prices |
---|
Akers Biosciences, Inc. (AKR) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price